Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dror Ortho-Design, Inc.DROR · Entity 8012 | Director · Chief Technology Officer | June 17, 2024 | June 25, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dror Ortho-Design, Inc.
Report date June 17, 2024 · Filed June 25, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2034-06-17 | Direct | 57,578,694 |
Reported balance
After 2024-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-17 · Grant · Acquired 57,578,694 · Balance 57,578,694 F1: The stock options vested two-thirds upon the date of grant, and the remainder vests on December 6, 2024, subject to earlier vesting upon the achievement of patient use objectives, provided the Reporting Person is employed by or providing services to the Issuer or an affiliate on the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options vested two-thirds upon the date of grant, and the remainder vests on December 6, 2024, subject to earlier vesting upon the achievement of patient use objectives, provided the Reporting Person is employed by or providing services to the Issuer or an affiliate on the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2024 Filed Jun 25, 2024 17:30 UTC | Dror Ortho-Design, Inc. DROR · Entity 8012 | GrantStock Option (Right to Buy) · Derivative | 57,578,694 | $0.00 Strike: $0.00 | $213,041.17 |
DisclosureSEC source: 0001213900-24-055836 · ownership.xml · derivative · entry 1 Shvets Moshe · CIK 0001993398 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,578,694 Underlying: Common Stock · 57,578,694 shares Expires 2034-06-17 F1 · derivative.exercise_date: The stock options vested two-thirds upon the date of grant, and the remainder vests on December 6, 2024, subject to earlier vesting upon the achievement of patient use objectives, provided the Reporting Person is employed by or providing services to the Issuer or an affiliate on the applicable vesting date. Read SEC document |
| August 14, 2023 Filed Sep 27, 2023 21:31 UTC | Dror Ortho-Design, Inc. DROR · Entity 8012 | GrantCommon Warrants · Derivative | 26,141,712 | Not disclosed Strike: $0.03 | Not disclosed |
DisclosureSEC source: 0001387131-23-011680 · shvets_form4-092723.xml · derivative · entry 2 Shvets Moshe · CIK 0001993398 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,141,712 Underlying: Common Stock · 26,141,712 shares Expires not disclosed F6 · price: Pursuant to a Warrant Exchange Agreement, dated August 14, 2023, between the Company and the reporting person, simultaneously with the Share Exchange, warrants to purchase 7,109 ordinary shares of Private Dror, representing all warrants to purchase ordinary shares of Private Dror held by the reporting person, were cancelled, and the Company issued to the reporting person warrants to purchase shares of the Company's Common Stock with an exercise price of $0.033 per share (the "Warrant Exchange"). F4 · derivative.exercise_date: Warrants will be exercisable from and after the date the Company has reserved shares of Common Stock on behalf of the holders of the warrants (the "Initial Exercise Date"). F5 · derivative.expiration_date: Warrants expire on the fifth anniversary of the Initial Exercise Date. Read SEC document |
| August 14, 2023 Filed Sep 27, 2023 21:31 UTC | Dror Ortho-Design, Inc. DROR · Entity 8012 | GrantSeries A Convertible Preferred Stock · Derivative | 691,620.94 | Not disclosed Strike: $0.01 | Not disclosed |
DisclosureSEC source: 0001387131-23-011680 · shvets_form4-092723.xml · derivative · entry 1 Shvets Moshe · CIK 0001993398 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 691,620.94 Underlying: Common Stock · 69,162,094 shares Expires not disclosed F3 · price: Pursuant to a Share Exchange Agreement, dated July 5, 2023 (as amended, the "Share Exchange Agreement"), by and among the Company, Dror Ortho-Design Ltd. ("Private Dror"), and the shareholders of Private Dror, the reporting person transferred 18,808 ordinary shares of Private Dror, representing all ordinary shares of Private Dror held by the reporting person, to the Company in exchange for shares of Preferred Stock (the "Share Exchange"). F1 · derivative.exercise_date: Shares of Series A Convertible Preferred Stock, par value $0.0001 per share and with a stated value of $1.10 per share (the "Preferred Stock") of Dror Ortho-Design, Inc. (formerly Novint Technologies, Inc.) (the "Company") shall be convertible, at any time and from time to time at the option of the Holder thereof, into shares of the company's common stock, par value $0.0001 per share (the "Common Stock") from and after the date the Company has reserved shares of Common Stock on behalf of the holders of the Preferred Stock. F2 · derivative.expiration_date: The Preferred Stock is perpetual and therefore has no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.